Invivyd, Inc.

Invivyd, Inc. is a biotechnology company focused on the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. Its lead product is Pemivibart, a half-life extended investigational monoclonal antibody marketed under the PEMGARDA brand, used for pre-exposure prophylaxis of COVID-19 in adults and adolescents via injection. The company also has VYD2311, a monoclonal antibody in Phase III clinical trials for SARS-CoV-2, and VBY329, a preclinical monoclonal antibody targeting respiratory syncytial virus and measles in neonates, infants, and children. Invivyd collaborates with Adimab, LLC for antibody discovery and optimization.

Invivyd, Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol IVVD. Its shares are traded in US dollars (USD). The company is headquartered in New Haven, Connecticut, and operates primarily in the United States.

Invivyd operates in the Healthcare sector and is classified under the Biotechnology industry. As a biotechnology firm, it specializes in developing antibody-based therapies for viral infectious diseases, leveraging its research and development capabilities to create treatments for conditions such as COVID-19 and respiratory syncytial virus.

Invivyd is headquartered in New Haven, Connecticut, United States. The company primarily serves the US market, focusing on the prevention and treatment of viral infectious diseases through its antibody therapies. Its products and pipeline candidates are developed for use in adults, adolescents, and pediatric populations, including neonates and infants.

Invivyd generates revenue through the commercialization of antibody therapies, with its first marketed product being Pemivibart (PEMGARDA) for COVID-19 pre-exposure prophylaxis. The company's pipeline includes VYD2311, a monoclonal antibody in Phase III trials for SARS-CoV-2, and VBY329, a preclinical candidate for respiratory syncytial virus and measles. Invivyd also collaborates with Adimab, LLC to discover and optimize proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. before rebranding in September 2022 and was incorporated in 2020.